Candesartan improves maximal exercise capacity in hypertensives: Results of a randomized placebo-controlled crossover trial

Journal of Clinical Hypertension

Volumn 11, Issue 4, 2009, Pages 192-200

  De Rosa, Maria Leonarda ^a   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; ECHOCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WORK; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VENOUS OXYGEN TENSION;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BENZIMIDAZOLES; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PLATELET AGGREGATION INHIBITORS; SINGLE-BLIND METHOD; TETRAZOLES; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 65449154717     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00095.x     Document Type: Article

References (42)

1. Modesti PA, Olivo G, Carrabba N, et al. Early impairment of the cardiopulmonary exercise capacity of hypertensive patients. Int J Cardiol. 1994;44:163-169.
2. National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program: The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda: National Institutes of Health; 1997
3. Smith DH, Neutel JM, Graettinger WF, et al. Impact of LV hypertrophy on blood pressure responses to exercise. Am J Cardiol. 1992;69:225-228.
4. Maxwell AJ, Schauble E, Bernstein D, et al. Limb blood flow during exercise is dependent on nitric oxide. Circulation. 1998;98:369-374.
5. Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998;98:2709-2715.
6. Tanaka H, Reiling MJ, Seals DR. Regular walking increases peak limb vasodilatory capacity of older hypertensive humans: Implication for arterial structure. J Hypertens. 1998;16:423-428.
7. Vaitkevicius PV, Fleg JL, Engel JH, et al. Effects of age and aerobic capacity on arterial stiffness in healthy adults. Circulation. 1993;88:1456-1462.
8. Awan NA, Mason DT. Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Am Heart J. 1996;131:177-185.
9. Puri S, Baker BL, Dutka DP, et al. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation. 1995;91:2769-2774.
10. Guazzi M, Marenzi GC, Alimento M, et al. Improvement of alveolar-capillary diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation. 1997;95:1930-1936.
11. Eberhardt RT, Kevak RM, Kang PM, et al. Angiotensin II receptor blockade: An innovative approach to cardiovascular pharmacotheraphy. J Clin Pharmacol. 1993;33:1023-1038.
12. Hamroff G, Blaufarb I, Mancini D, et al. Angiotensin II-receptor blockade further reduces after load safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol. 1997;30:533-536.
13. Gleiter CH, Jagle C, Gresser U, et.al. Candesartan. Cardiovasc Drug Rev. 2004;22(4):263-284.
14. Vidt DG, White WB, Ridley E, et al; CLAIM Study Investigators. A forced titration study of antihypertensive efficacy of candesartan cilexitil in comparison to losartan: CLAIM Study II. J Hum Hypertens. 2001;15(7):475-480.
15. Schiller NB, Shah PM, Crawford M. American Society of Echocardiography Committee on Standard, Subcommittee on Quantitation of Two-Dimensional Echocardiograms: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:258-367.
16. Evans MA, Burnett JC Jr, Redfield MM. Effect of low dose aspirin on cardio renal function and acute hemodynamic response to enalapril in a canine model of severe heart failure. J Am Coll Cardiol. 1995;25:1445-1450.
17. Guazzi M, Melzi G, Agostoni PG. Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997;80:1572-1576.
18. Conway J, Coats A. Value of ambulatory blood pressure monitoring in clinical pharmacology. J Hypertens. 1989;7(suppl):S29-S32.
19. Rautahatju PM, Park LP, Chaitman BR, et al. The Novacode criteria for classification of ECG abnormalities and their clinically significant progression and regression. J Electrocardiol. 1998;31(3):157-187.
20. Devereux RB, Roman MJ. Evaluation of cardiac and vascular structure by echocardiography and other noninvasive technique. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Treatment, 2nd ed. New York, NY: Raven Press; 1995:1969-1985.
21. Sahn DJ, De Maria A, Kisslo J. The Committee on Mmode Standardization of the American Society of Echocardiography: Recommendations regarding quantitation in M-mode echocardiography. Results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
22. Jones NL. Clinical Exercise Testing. London, England: WB Saunders; 1988.
23. Myers J, Froelicher VF. Optimizing the exercise test for pharmacological investigations. Circulation. 1990;82:1839-1846.
24. Wasserman K, Hansen JE, Sue DY. Principles of Exercise Testing Interpretation. Philadelphia, PA: Lea & Febiger; 1986.
25. Mudge GH, Goldstein S, Addonizio LJ. 24th Bethesda conference taskforce 3: Heart transplaRtation: recipient guidelines/prioritization. J Am Coll Cardiol. 1993;22:21-31.
26. Marburger CT, Brubaker PH, Pollock WE, et al. Reproducibility of cardiopulmonary exercise testing in elderly patients with congestive heart failure. Am J Cardiol. 1998;82:905-909.
27. Missault LH, Duprez DA, Brandt AA, et al. Exercise performance and diastolic filling in essential hypertension. Blood Press. 1993;2:284-288.
28. Olsen MH, Meyer C, Wachtell K. The importance of changes in conduit and peripheral arteries for coronary flow reserve in patients with hypertension: A LIFE sub study. J Am Coll Cardiol. 1999;33:279.
29. Drayer JIM, Gardin JM, Weber MA. Antihypertensive therapy and changes in echocardiographic LV muscle mass. Clin Pharmacol Ther. 1984;35:236-241.
30. Fagard R, Bielen E, Hespel P. Physical exercise in hypertension. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press; 1990:1985-1998.
31. Vyssoulis GP, Kouremetis MT, Valiouli MA, et al. Effect of beta-blockade on exercise capacity in hypertensive subjects: A one-year double-blind study of celiprolol and metoprolol. Cardiovasc Drugs Ther. 1995;9:133-139.
32. Guazzi M, Palermo P, Pontone G, et al. Sinergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol. 1999;84(1):1038-1043.
33. Vescovo G, Dalla Libera L, Serafini F, et al. Improved exercise tolerance after losartan and enalapril in heart failure Correlation with changes in skeletal muscle heavy chain composition. Circulation. 1998;98:1742-1749.
34. Wasserman K. Coupling of external to cellular respiration during exercise: The wisdom of the body revisited. Am J Physiol. 1994;266:E519-E539.
35. Hollenberg NK, Fisher NDL, Price DA. Pathways for angiotensin II generation in intact human tissue. Evidence from comparative pharmacological interruption of renin system. Hypertension. 1998;32:387-392.
36. Corrà U, Mezzani A, Bosimini E, et al. Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity. Am Heart J. 2002;143(3):418-426.
37. Little WC, Wesley-Farrington DJ, Hoyle J, et al. Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction. J Cardiovasc Pharmacol. 2004;43(2):288-293.
38. Wilson JR, Ferraro N. Effect of the renin-angiotensin system on limb circulation and metabolism during exercise in patients with heart failure. Am J Cardiol. 1985;6:56-63.
39. Stevenson LW, Steimle AE, Fonarow G. Improvement in exercise capacity of candidates awaiting heart transplantation. J Am Coll Cardiol. 1995;25:163-170.
40. Pitt B, Segal R, Martinez FA. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly Study, ELITE). Lancet. 1997;349:747-752.
41. Blaufarb IS, Sonnenblick EH. The renin-angiotensin system in LV remodeling. Am J Cardiol. 1996;77:8C-16C.
42. Michelsen S, Knutsen KM, Stugaard M, et al. Is LV mass in apparently normotensive men correlated to maximal blood pressure during exercise? Eur Heart J. 1990;11:241-248.